Does innovation in obesity drugs affect stock markets? An event study analysis

Gaceta Sanitaria

Volumn 26, Issue 4, 2012, Pages 352-359

  Pérez Rodríguez, Jorge V ^a   González López Valcárcel, Beatriz ^a  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Abnormal returns; Drug innovation; Event study; Market model; Obesity drugs; R D

Indexed keywords

ANTIOBESITY AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ARTICLE; DRUG INDUSTRY; ECONOMICS; EXPERIMENTAL THERAPY; HUMAN; MARKETING; RESEARCH;

ANTI-OBESITY AGENTS; DRUG INDUSTRY; HUMANS; MARKETING; PIPERIDINES; PYRAZOLES; RESEARCH; THERAPIES, INVESTIGATIONAL;

EID: 84863227904     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/j.gaceta.2011.07.028     Document Type: Article

References (56)

1. Senard J.M., Montastruc P., Herxheimer A. Early warnings about drugs-from the stock market. Lancet 1996, 347:987-988.
2. Ferguson J.R. Biomedical research and insider trading. N Engl J Med 1997, 337:631-634.
3. Steinbrook R. Financial conflicts of interest and the Food and Drug Administration's Advisory Committees. N Engl J Med 2005, 353:116-118.
4. Topol E.J., Blumenthal D. Physicians and the investment industry. JAMA 2005, 293:2654-2657.
5. Evens R. Drug and biological development. From molecule to product and beyond 2007, Springer Science + Business Media, New York.
6. Ahmed P., Gardella J., Nanda S. Wealth effect of drug withdrawals on firms and their competitors. Financial Management 2002, 31:21-41.
7. Dranove D., Olsen C. The economic side effects of dangerous drug announcements. Journal of Law & Economics 1994, 37:323-348.
8. Jarrell G., Peltzman S. The impact of product recalls on the wealth of sellers. Journal of Political Economy 1985, 93:512-536.
9. Lang L., Stulz R. Contagion and competitive intra-industry effects of bankruptcy announcements: an empirical analysis. Journal of Financial Economics 1992, 32:45-60.
10. Hara T. Innovation in the pharmaceutical industry: the process of drug discovery and development 2003, Edward Elgar, Cheltenham, UK.
11. WHO. Global strategy on diet, physical activity and health. Obesity and overweight. Available from: . http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf.2003.
12. Rodríguez Caro A., González López-Valcárcel B. El trasfondo económico de las intervenciones sanitarias en la prevención de la obesidad. Revista Española de Salud Pública 2009, 83:25-41.
13. Noel P.H., Pugh J.A. Management of overweight and obese adults. BMJ 2002, 325:757-761.
14. Bray G.A., Ryan D.H. Drug treatment of the overweight patient. Gastroenterology 2007, 132:2239-2252.
15. Goodyear L.J. The exercise pill --too good to be true?. N Engl J Med 2008, 359:1842-1844.
16. Vincent R.P., le Roux C.W. New agents in development for the management of obesity. Int J Clin Pract 2007, 61:2103-2112.
17. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588.
18. Davidoff R., McTiernan A., Constantine G., et al. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001, 161:1429-1436.
19. Gardin J.M., Schumacher D., Constantine G., et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000, 283:1703-1709.
20. Gardin J.M., Weissman N.J., Leung C., et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001, 286:2011-2014.
21. Moloo J., Jackson K.L., Waller J.L., et al. Xenotransmission of the socioeconomic gradient in health?. A population based study. BMJ 1998, 317:1686.
22. Rothman R.B., Baumann M.H., Savage J.E., et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102:2836-2841.
23. Shively B.K., Roldan C.A., Gill E.A., et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999, 100:2161-2167.
24. Marx J. Drug development. Drugs inspired by a drug. Science 2006, 311:322-325.
25. Brown S., Warner J. Measuring security price performance. Journal of Financial Economics 1980, 8:205-258.
26. Brown S., Warner J. Using daily stock returns. The case of event studies. Journal of Financial Economics 1985, 14:3-31.
27. Fama E. Foundation of finance 1976, Basic Books, New York.
28. Fama E., Fisher L., Jensen M., et al. The adjustment of stock prices to new information. International Economic Review 1969, 10:1-21.
29. MacKinlay A. Event studies in economics and finance. Journal of Economic Literature 1997, 35:13-39.
30. Dowdell T., Govindaraj S., Jain P. The Tylenol incident, ensuing regulation, and stock prices. The Journal of Financial and Quantitative Analysis 1992, 27:283-301.
31. Bel G. Privatization on the stock market: sale at one go or sale in tranches?. Economics Letters 1998, 58:113-117.
32. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
33. Sanofi-Aventis. Press release October 29 2008. FDA approves rapid-acting insulin Apidra® for treatment of children with diabetes. 2008. Available from: . http://en.sanofi-aventis.com/press/press_releases/2008/ppc_22457.asp.
34. Steinbrook R. Wall Street and clinical trials. N Engl J Med 2005, 353:1091-1093.
35. Azoulay P. Do pharmaceutical sales respond to scientific evidence?. Journal of Economics and Management Strategy 2002, 11:551-594.
36. Golec J, Vernon J. What's the " interest" in FDA drug advisory committee conflicts of interest? NBER Working Paper. 2009. 14932.
37. Pérez-Rodríguez J, López-Valcárcel B. Do product innovation and news about the R&D process produce large price changes and overreaction? The case of pharmaceutical stock prices. Applied Economics. 2011; Forthcoming.
38. Filson D. The impact of e-commerce strategies on firm value: lessons from Amazon.com and its early competitors. The Journal of Business 2004, 77:135-154.
39. Loury G. Market structure and innovation. The Quarterly Journal of Economics 1979, 93:395-410.
40. Lee T., Wilde L. Market structure and innovation: a reformulation. The Quarterly Journal of Economics 1980, 94:429-436.
41. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
42. Van Gaal L.F., Scheen A.J., Rissanen A.M., et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008, 29:1761-1771.
43. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
44. Scheen A.J., Finer N., Hollander P., et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672.
45. Anthenelli R. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial (Smoking Cessation in Smokers Motivated to Quit). Presented at: American College of Cardiology Scientific Sessions 2004.
46. Rosenstock J., Hollander P., Chevalier S., et al. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008, 31:2169-2176.
47. Nissen S.E., Nicholls S.J., Wolski K., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008, 299:1547-1560.
48. Rinaldi-Carmona M., Barth F., Heaulme M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350:240-244.
49. Arnone M., Maruani J., Chaperon F., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997, 132:104-106.
50. Di Marzo V., Goparaju S.K., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
51. Ravinet Trillou C., Arnone M., Delgorge C., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.
52. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
53. Gary-Bobo M., Elachouri G., Scatton B., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006, 69:471-478.
54. Christensen R., Kristensen P.K., Bartels E.M., et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
55. Van Gaal L., Pi-Sunyer X., Despres J.P., et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31(Suppl 2):S229-S240.
56. Schafer A., Pfrang J., Neumuller J., et al. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 2008, 154:1047-1054.